Ruxolitinib as GVHD Prophylaxis in AA Patients
NCT05914714
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
46
Enrollment
OTHER
Sponsor class
Conditions
The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA
Interventions
DRUG:
Ruxolitinib 5 MG BID Oral Tablet
Sponsor
Institute of Hematology & Blood Diseases Hospital, China